Castle biosciences to acquire previse

Expected to complement castle's current gastroenterology franchise adds methylation technology developed at the johns hopkins university school of medicine and additional technologies in development friendswood, texas, may 05, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire capsulomics, inc., d/b/a previse. previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer.
CSTL Ratings Summary
CSTL Quant Ranking